Foreign air travelers to the U.S. are required to have full vaccination, proof of negative test before boarding, and follow-up negative test within three days of entering U.S.
FRIDAY, Oct. 15, 2021 (HealthDay News) — All international travelers who are fully vaccinated against the coronavirus will be able to enter the United States beginning Nov. 8, an official at the White House told The New York Times.
The announcement came on the heels of news on Wednesday that the United States would reopen its land borders to fully vaccinated travelers from Canada and Mexico for the first time since pandemic closures began 19 months ago. U.S. officials had previously said that foreign travelers by air who were fully vaccinated would be allowed to enter the country beginning in early November, but no set date had been given.
Friday’s announcement effectively completes the reopening of the United States to tourism and visits from family living abroad, ushering in a new phase in the pandemic recovery.
The reopening comes with tough requirements for air travelers: full vaccination, proof of a negative coronavirus test before boarding their plane, and a follow-up negative COVID-19 test conducted within three days of entering the United States, the Times said. Unvaccinated foreign travelers will continue to be banned from entering the country, officials told the Times. Unvaccinated Americans flying home from overseas will be required to test negative for the coronavirus one day before they return to the United States, and they must also show proof that they have bought a follow-up test to take after arriving in the United States.
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older
Most U.S. Adults Unsure Which Vaccines CDC Recommends During Pregnancy
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Risk for Herpes Zoster Elevated for Individuals With Atopic Dermatitis
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV